Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
February 15, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
The Global Hematology Diagnostics Market Revenue totaled USD 780 million in 2023 and is expected to reach USD 2 billion by 2033 | Future Market Insights, Inc.
February 10, 2023 06:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The Hematology Diagnostics Market is expected to be worth $780.0 million in 2023 and $2.0 billion by 2033. During the forecast period, the market for...
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
January 18, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, US and MAINZ, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early...
Mainz Biomed Provides Year-End 2022 Corporate Review
January 03, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, US and MAINZ, Germany , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
December 20, 2022 03:01 ET
|
Mainz BioMed NV
Enrollment remains on track to complete in Q1 2023 with results in 1H 2023Potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to colorectal cancer (CRC) BERKELEY,...
Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
December 06, 2022 03:01 ET
|
Mainz BioMed NV
ReconAAsense study examining the clinical performance of mRNA and DNA test combined with a fecal immunochemical test for early detection of advanced adenoma and colorectal cancer to enroll 15,000...
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
November 29, 2022 08:00 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Canon Medical Celebrates 30th Anniversary of Hybrid Angio-CT Technology with World’s First Deep Learning Spectral CT Reconstruction and HD 76 Technology Integration into Alphenix 4D CT System
November 28, 2022 09:00 ET
|
Canon Medical Systems USA
Tustin, California, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Canon Medical Systems USA, Inc., a global leader in innovative diagnostic imaging technology, is proud to celebrate the 30th anniversary of...
Diagnostic Imaging Market Size is projected to reach USD 48 billion by 2029, with growth at a CAGR of 5.6% over the forecast period 2022-2029
November 23, 2022 10:00 ET
|
DataM Intelligence
ENTERPRISE, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Diagnostic Imaging Market Size Share Growth Insights: According to the research report published by DataM Intelligence, the global Diagnostic...
Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
November 22, 2022 08:00 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...